Administration of the allogeneic CAR T-cell therapy cemacabtagene ansegedleucel (cema-cel) as first-line consolidation led to improvements in minimal residual disease (MRD) negativity rates compared with observation in patients with large B-cell lymphoma (LBCL), according to data from the pivotal phase 2 ALPHA3 trial (NCT06500273).1
Findings announced by Allogene Therapeutics showed that evaluable patients treated with cema-cel (n = 12) achieved an MRD negativity rate of 58.3% compared with 16.7% for patients who underwent observation (n = 12). At the first MRD assessment at day 45, patients in the cema-cel arm achieved a median circulating tumor DNA clearance of 97.7% over baseline, compared with 26.6% in the observation arm.
“Early MRD clearance in this setting is encouraging and supports the potential for cema-cel to change how we approach high-risk LBCL at the end of first-line therapy,” Zachary Roberts, MD, PhD, executive vice president of Research and Development and chief medical officer of Allogene Therapeutics, stated in a news release. “These interim data suggest that an off-the-shelf [CAR T-cell therapy] may be able to intervene during that important window before clinical relapse to eliminate residual disease and make earlier intervention feasible in routine clinical practice. We look forward to the next study milestones as the trial continues to further define the potential of cema-cel.”
How is the ALPHA3 trial being conducted?
The ongoing, multicenter, open-label, randomized study is enrolling patients at least 18 years of age with LBCL per World Health Organization 2017 criteria, including diffuse LBCL, high-grade B-cell lymphoma, and primary mediastinal B-cell lymphoma.2 Completion of first-line therapy is required, and no additional lines of therapy are allowed; patients need to be in complete response or partial response suitable for observation at the end of first-line therapy. An ECOG performance status of 0 or 1, along with adequate hematologic, renal, hepatic, pulmonary, and cardiac function, are required.
Patients also need to have MRD-positive disease, per assessment with the Foresight CLARITY IUO MRD test.
Key exclusion criteria comprise LBCL with a history of central nervous system involvement or transformation from another malignancy; prior treatment with anti-CD19 therapies; and active and clinically significant autoimmune disease.
Cema-Cel Improves MRD Clearance as First-Line LBCL Consolidation
- In the phase 2 ALPHA3 trial, first-line consolidation with cema-cel produced higher MRD negativity rates vs observation (58.3% vs 16.7%) in patients with LBCL who remained MRD-positive after initial therapy.
- At day 45, median ctDNA clearance rates reached 97.7% with cema-cel compared with 26.6% with observation.
- Cema-cel demonstrated a favorable early safety profile, with no reported any-grade CRS, ICANS, or GVHD. Efficacy end points including EFS, PFS, and OS remain blinded.
Patients are being randomly assigned to receive cema-cel or standard-of-care observation. In the treatment arm, patients are receiving fludarabine and cyclophosphamide lymphodepletion prior to cema-cel.
Investigators conducted an interim futility analysis after the first 24 patients were randomly assigned; MRD status is being assessed at day 45, month 3, and then every 3 months during the first year of follow-up.1
Event-free survival (EFS) is serving as the trial’s primary end point. Key secondary end points include progression-free survival (PFS) and overall survival (OS). Data for these end points remained blinded as of the interim futility analysis.
What was reported regarding the safety of cema-cel?
As of data cutoff, no serious adverse effects (AEs) were reported among patients treated with cema-cel. Notably, no instances of any-grade cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), or graft-vs-host disease (GVHD) were observed. Any-grade infections occurred in 16.7% of patients in both arms, and no grade 3 or higher infections were reported in either group. Fifty percent of patients in the cema-cel arm experienced other neurologic AEs compared with 8.3% of patients in the observation arm; no grade 3 or higher other neurologic AEs occurred in either group.
“The early safety profile, characterized by an absence of CRS and ICANS, is encouraging given its potential to enable safe outpatient management,” Nancy L. Bartlett, MD, a professor of medicine in the Division of Oncology at Washington University School of Medicine and a physician at Siteman Cancer Center in St. Louis, Missouri, added in the news release. “When considered alongside the availability of an off-the-shelf product, these findings suggest the possibility of overcoming key logistical barriers that have historically limited broader use of [CAR T-cell therapy], particularly in earlier lines of therapy. Coupled with the encouraging MRD clearance data, this approach may represent an important step toward improving outcomes [and] expanding patient access.”
What’s next for the ALPHA3 trial and cema-cel?
Investigators intend to enroll approximately 220 patients onto the trial, with accrual expected to be completed by the end of 2027.
An interim EFS analysis is anticipated in the middle of 2027, with a primary analysis expected in the middle of 2028. If the readout of positive data continues, findings from ALPHA3 could support the submission of a biologics license application seeking the approval of cema-cel.
References
- Allogene Therapeutics reports interim futility analysis from pivotal ALPHA3 trial showing 58.3% MRD clearance with cemacabtagene ansegedleucel (cema-cel) vs. 16.7% in observation arm in first-line consolidation LBCL. News release. Allogene Therapeutics. April 13, 2026. Accessed April 13, 2026. https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-reports-interim-futility-analysis-pivotal
- Consolidation of first-line MRD+ remission with cema-cel in patients with LBCL (ALPHA3). ClinicalTrials.gov. Updated March 18, 2026. Accessed April 13, 2026. https://clinicaltrials.gov/study/NCT06500273
